Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
BONESUPPORT HOLDING AB is a Swedish orthobiologics company headquartered in Lund, specializing in the development and commercialization of innovative injectable bio-ceramic bone graft substitutes. Its flagship technology platform, CERAMENT, produces synthetic, osteoconductive biomaterials that remodel into the patient’s own bone within 6 to 12 months and can elute antibiotics like gentamicin for infection control. These products treat conditions such as fragility fractures from osteoporosis, bone voids from trauma or surgery, benign tumors, and osteomyelitis, supporting orthopedic procedures including fracture augmentation and spine support. Founded in 1999 by Professor Lars Lidgren, the company has raised over SEK 500 million in venture capital and went public on Nasdaq Stockholm in 2017. CERAMENT received FDA approval in 2005 and CE marking in 2009, with CERAMENT G designated a breakthrough device by the FDA in 2020. In 2024, BONESUPPORT HOLDING AB reported net sales of SEK 899 million, underscoring its growing role in the global medical device market for bone healing solutions.